Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Kai-Liang Tang, Han-Ying Tang, Yi- Du, Tian Tian & Shi-Jiang Xiong. (2019) MiR-638 suppresses the progression of oral squamous cell carcinoma through wnt/β-catenin pathway by targeting phospholipase D1. Artificial Cells, Nanomedicine, and Biotechnology 47:1, pages 3278-3285.
Read now
Read now
Articles from other publishers (14)
Liyong Deng, Kuiyu Gong & Guihua Wang. (2022) Hsa_circ_0008344 Promotes Glioma Tumor Progression and Angiogenesis Presumably by Regulating miR-638/SZRD1 Pathway. Neurotoxicity Research 40:3, pages 825-836.
Crossref
Crossref
Ke FangXuan ChenFeng QiuJinbiao XuHuanwen XiongZhanmin Zhang. (2022) Serum-Derived Exosomes-Mediated Circular RNA ARHGAP10 Modulates the Progression of Non-Small Cell Lung Cancer Through the miR-638/FAM83F Axis. Cancer Biotherapy and Radiopharmaceuticals 37:2, pages 96-110.
Crossref
Crossref
Bin Wang, Kun Wang, Jian Yu, Xiao-meng Hao, Yu-lu Liu & Ai-Yan Xing. (2022) miR-638 Serves as a Biomarker of 5-Fluorouracil Sensitivity to Neoadjuvant Chemotherapy in Breast Cancer. Journal of Breast Cancer 25:3, pages 193.
Crossref
Crossref
Li Ma, Wei Zhang, Yaofeng Jin, Xiaomei Bai & Qiaoling Yu. (2021) miR‑638 suppresses proliferation by negatively regulating high mobility group A1 in ovarian cancer cells. Experimental and Therapeutic Medicine 22:5.
Crossref
Crossref
Ye Zhang, Hongmin Yao, Ying Li, Lu Yang, Liang Zhang, Jinxin Chen, Yong Wang & Xia Li. (2021) Circular RNA TADA2A promotes proliferation and migration via modulating of miR‑638/KIAA0101 signal in non‑small cell lung cancer. Oncology Reports 46:3.
Crossref
Crossref
Zhi Xiong Chong, Swee Keong Yeap & Wan Yong Ho. (2021) Dysregulation of miR-638 in the progression of cancers. Pathology - Research and Practice 220, pages 153351.
Crossref
Crossref
Lixia Hu, Mengqin Huang, Qianqian Yuan & Fanliang Kong. (2021) Prognostic and clinicopathological significance of miR-638 in cancer patients. Medicine 100:15, pages e25441.
Crossref
Crossref
Pei Xu, Lei Wang, Xiao Xie, Fengqing Hu, Qi Yang, Rui Hu, Lianyong Jiang, Fangbao Ding, Ju Mei, Jianhui Liu & Haibo Xiao. (2020) Hsa_circ_0001869 promotes NSCLC progression via sponging miR-638 and enhancing FOSL2 expression. Aging 12:23, pages 23836-23848.
Crossref
Crossref
Huiling Yan & Meng Guo. (2020)
Schizandrin A inhibits cellular phenotypes of breast cancer cells by repressing
miR
‐155
. IUBMB Life 72:8, pages 1640-1648.
Crossref
Crossref
Jianjiao Ni, Shanhui Liang, Boer Shan, Wenjuan Tian, Huaying Wang & Yulan Ren. (2020) Methylation‑associated silencing of miR‑638 promotes endometrial carcinoma progression by targeting MEF2C. International Journal of Molecular Medicine.
Crossref
Crossref
Qiu-Yan Lin, Jia-Qi Wang, Li-Li Wu, Wei-E Zheng & Pei-Rui Chen. (2019) miR-638 represses the stem cell characteristics of breast cancer cells by targeting E2F2. Breast Cancer 27:1, pages 147-158.
Crossref
Crossref
Eleni Zografos, Flora Zagouri, Despoina Kalapanida, Roubini Zakopoulou, Anastasios Kyriazoglou, Kleoniki Apostolidou, Maria Gazouli & Meletios-Athanasios Dimopoulos. (2019) Prognostic role of microRNAs in breast cancer: A systematic review. Oncotarget 10:67, pages 7156-7178.
Crossref
Crossref
Aksana N. Kucher. (2019) Sensitive to the effects of environmental factors miR-638 and common diseases. Ecological genetics 17:3, pages 99-110.
Crossref
Crossref
Carmela Dell’Aversana, Francesca Cuomo, Chiara Botti, Ciro Maione, Annamaria Carissimo, Amelia Casamassimi, Lucia Altucci & Gilda Cobellis. (2019) Hypoxia-Regulated miRNAs in Human Mesenchymal Stem Cells: Exploring the Regulatory Effects in Ischemic Disorders. International Journal of Molecular Sciences 20:6, pages 1340.
Crossref
Crossref